Recent evidence suggests that the oral drug Fingolimod (FTY720) for relapsing-remitting multiple sclerosis (MS) may act directly on the central nervous system (CNS) and modulate disease pathogenesis and progression in experimental models of MS. However, the specific subtype of sphingosine-1-phosphate (S1P) receptors that mediates the effect of FTY720 on the CNS cells has not been fully elucidated. Here, we report that S1P receptor 1 (S1PR1) is elevated in reactive astrocytes in an autoimmunity independent mouse model of MS and that selective S1PR1 modulation is sufficient to ameliorate the loss of oligodendrocytes and demyelination. The non-selective S1PR modulator, FTY720, or a short-lived S1PR1-specific modulator, CYM5442, was administered daily to mice while on cuprizone diet. Both FTY720-and CYM5422-treated mice displayed a significant reduction in oligodendrocyte apoptosis and astrocyte and microglial activation in comparison to vehicle-treated groups, which was associated with decreased production of proinflammatory mediators and down-regulation of astrocytic S1PR1 protein. Interestingly, S1PR1 modulation during the early phase of cuprizone intoxication was required to suppress oligodendrocyte death and consequent demyelination as drug treatment from 10 days after the initiation of cuprizone feeding was no longer effective. CYM5442 treatment during the brief cuprizone exposure significantly prevented Il-1b, Il-6, Cxcl10, and Cxcl3 induction, resulting in suppression of subsequent reactive gliosis and demyelination. Our study identifies functional antagonism of S1PR1 as a major mechanism for the protective effect of FTY720 in the cuprizone model and suggests pathogenic contributions of astrocyte S1PR1 signaling in primary demyelination and its potential as a therapeutic target for CNS inflammation.
| I N TR ODU C TI ON
Multiple sclerosis (MS) is an inflammatory demyelinating disease of the central nervous system (CNS) characterized by progressive axonal damage and declining neurologic functions as a consequence of loss of oligodendrocytes and demyelination. While the etiology of MS remains elusive, the pathogenesis of MS involves aberrant activation of both adaptive and innate immune responses (Lassmann, 2014) . FTY720 (Fingolimod, Gilenya) is a first-in-class oral drug for relapsing-remitting MS that shows clinical efficacy in reducing the frequency and severity of relapses and slowing the progression of disability (Kappos et al., 2015) . FTY720 is a structural analog of sphingosine and is phosphorylated in vivo by sphingosine kinase II to phosphorylated FTY720 (pFTY720), which binds four of the five high-affinity G-protein-coupled sphingosine-1-phosphate (S1P) receptors (S1PR), namely S1PR1, 23, 24 and 25 , and modulates intracellular signaling pathways (Brinkmann et al., 2010) . The efficacy of FTY720 in patients with relapsingremitting MS has largely been attributed to functional antagonism of lymphocyte S1PR1 signaling as FTY720 treatment prevents lymphocyte egress from lymphoid organs through internalization and downregulation of surface S1PR1, thereby preventing CNS infiltration and destruction of myelin (Matloubian et al., 2004) . Increasing lines of evidence, however, have also suggested mechanisms other than interfering with lymphocyte recirculation may be involved as FTY720 readily crosses the blood-brain barrier (BBB) and becomes phosphorylated to its active form capable of acting directly on CNS parenchymal cells through engagement of specific S1P receptors (Foster et al., 2007; Groves, Kihara, & Chun, 2013; Miron, Schubart, & Antel, 2008) . Nearly all CNS resident cells including neurons, oligodendrocytes, microglia and astrocytes express various levels of specific subtype(s) of S1P receptors (Groves et al., 2013) . In MS lesions, the level of the natural S1PR ligand, S1P appears to be decreased (Qin, Berdyshev, Goya, Natarajan, & Dawson, 2010) whereas S1PR1 and S1PR3 expression is increased in reactive astrocytes (Brana et al., 2014; Van Doorn et al., 2010) . Interestingly, selective genetic ablation of S1pr1 in glial fibrillary acidic protein (GFAP)-expressing astrocytes ameliorates the clinical severity of experimental autoimmune encephalomyelitis (EAE), an animal model of MS, and mitigates the efficacy of systemically administered FTY720, suggesting potential pathogenic contribution of astroglial S1PR1 signaling pathways to disease progression as well as the CNS action mode of FTY720 during EAE (Choi et al., 2011) .
As EAE is primarily driven by autoreactive encephalitogenic T cells that are known sequestered by FTY720, the direct CNS impact of FTY720 has been investigated in autoimmunity-independent toxin models of CNS demyelination (Hu et al. 2011; Kim et al., 2011a) . Cuprizone intoxication in mice induces well-characterized demyelination in cerebral white matter (Matsushima & Morell, 2001; Steelman, Thompson, & Li, 2012) with multiple pathological characteristics of type III MS lesions (Lucchinetti et al., 2000) , and has been used to study primary demyelination as well as spontaneous myelin repair process after cuprizone withdrawal (Gudi, Gingele, Skripuletz, & Stangel, 2014) . The toxicant induces oligodendrocyte apoptosis and prominent microgliosis and astrogliosis in demyelinating regions with minimum peripheral immune cell infiltration (McMahon, Suzuki, & Matsushima, 2002) . This model is independent of T cell activation as demyelination and remyelination occur similarly between wild-type and lymphocyte-deficient Rag-1 2/2 mice (Arnett et al., 2001; Hiremath, Chen, Suzuki, Ting, & Matsushima, 2008 ) and the BBB remains intact (Gudi et al., 2014; Matsushima & Morell, 2001 ). Using this model, a recent study reported beneficial effects of FTY720 in ameliorating demyelination (Kim et al., 2011a) .
However, the mode of action and the specific subtype of S1PRs underlying the protective effect of FTY720 have not been identified. The present study set out to determine whether selective modulation of S1PR1 is sufficient to confer CNS protection against primay demyelination.
We have previously shown that ceramides, the bioactive sphingolipid in the sphingolipid metabolism pathway, are aberrantly accumulated in reactive astrocytes in actively demyelinating MS lesions and potentiates TNFa toxicity to oligodendrocytes (Kim, Steelman, Zhang, Kinney, & Li, 2012) . Ceramides are similarly upregulated in reactive astrocytes during cuprizone-induced demyelination while tissue S1P levels in the corpus callosum are significantly decreased (Kim et al., 2012) . The disrupted balance of ceramide/S1P during demyelination is reversed during the remyelination process (Kim et al., 2012) , suggesting that manipulation of S1P related signaling pathways may confer beneficial outcomes. In the present study, we examined the effect of the nonselective S1PR modulator FTY720 as well as a S1PR1 specific modulator, CYM5442 in the cuprizone model of demyelination and determined that direct and selective targeting the S1PR1 pathway is sufficient to abrogate CNS inflammatory responses, oligodendrocyte death, gliosis, and subsequent demyelination. , and #8) and 7 MS cases (#1-6, #13) were examined. The clinicopathologic information and neuropathologic findings on MS cases were described previously (Kim et al., 2012) .
| M A TER I A LS

| Use of laboratory animals
Mice were housed under constant 12-hr light/dark cycles in covered cages, and food and water were provided ad libitum. Animal protocols were approved by the Institutional Animal Care and Use Committee and studies performed in accordance with guidelines of the National Institutes of Health. Cuprizone-induced demyelination was achieved by feeding 8-9 week-old male C57BL/6 mice cuprizone milled into normal chow at a concentration of 0.2% (Harlan) for the duration of 8 days to 5 weeks as specified in figure legends. At the end of cuprizone feeding, some mice were returned to normal diet for an additional one week to
| 655 examine remyelination as described . Agematched naïve control mice were kept on standard diet throughout the duration of the cuprizone experiment. For drug administration, FTY720 was given daily intraperitoneally (i.p.) after dissolved in saline at a dose of 1 mg/kg body weight if not stated otherwise. CYM5442 was administered daily through i.p. injections after dissolved in water at 10 mg/kg body weight. Daily vehicle injected mice were used as controls for the drug treatment group.
| Generation of bone marrow chimeric mice
Bone marrow chimeric mice were generated as described previously (Zhuang et al., 2012 (4-5 weeks old) were subject to 10-Gy lethal dose irradiation and 4 hr later received 5.0 3 10 6 bone marrow cells from donor mice retro-orbitally. The recipients were kept in autoclaved cages with antibiotics-containing water and gammairradiated food for two weeks. Five weeks after bone marrow reconstitution, the chimeric mice were then subject to cuprizone diet.
| Mouse brain sample preparation for RNA, protein and lipid extraction
Mice were transcardially perfused with 20 ml of sterile PBS. The brain was removed, and the corpus callosum as well as portions of the cingulate gyrus and the external capsule was quickly but meticulously dissected using a sterile razor blade. Each piece of tissue was flash frozen in liquid nitrogen and stored at 2808C. The dissected brain regions were used for quantitative real-time polymerase chain reaction (qRT-PCR), Western blot analysis and sphingolipid quantification as we described previously (Kim et al., 2012) .
| qRT-PCR analysis
RNA was extracted with TRI reagent (Sigma), quantified with NanoDrop1000 spectrophotometer (ThermoFisher Scientific, Rockford, IL), treated with DNase I (Invitrogen) and reverse transcribed using a Promega AMV Reverse Transcriptase Kit (Madison, WI). Specific cDNAs were amplified and analyzed using a CFX384 Touch RT-PCR Detection System (Bio-Rad). Primers used in this study were summarized in Table   1 . Gene expression was normalized to b-actin and fold expression was calculated using the formula 2 -DDCt .
2.6 | Immunohistochemistry, terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL), and immunofluorescence microscopy
Tissue sections were rinsed with Tris-buffered saline (TBS; 50 mM Tris-HCl, pH 7.4, 150 mM NaCl) and blocked with TBS-T (0.1% Triton X-100) containing 5% goat serum for 1 hr at room temperature.
Sections were then incubated overnight at 48C with antibodies against Iba1 (1:500), GFAP (1:200), CNPase (1:100), GST-p (1:500), PLP (1:50), Olig2 (1:200), S1PR1 (1:50), MHC II (1:100), or CD68 
(1:100 showed most prominent and consistent gliosis and demyelination . Image J program was used for analysis including intensity measurement and cell counting.
| Myelin staining and demyelination scoring
Myelin was stained with 0.5% Sudan black in 70% ethanol or oil red O as described (Kim et al., 2012) . To assess the extent of demyelination, tissue images taken from 0 to 0.6 mm lateral and 21 to 22 mm from bregma were used. The extent of demyelination was scored in a blinded fashion by two independent investigators with scores ranging from 0 (normal level of myelin) to 4 (no myelin) as detailed previously . Two and three sections per animal were analyzed for vehicle and CYM5442 group, respectively. In a subset of studies (Supporting Information, Figure S3 ), demyelinated area, cellularity, and PLP-negative (PLP 2 ) area were used as an indication of tissue damage and repair as described (Steelman et al., 2016) . For lesion area measurement, 43 fluorescence images containing the lesion were captured at a constant exposure time, transformed into binary images and PLP negative area of the total lesion area was analyzed using Image J. Relative cellularity was measured based on bisbenzimide staining after transformed into binary images. Imager ChemiDoc XRS1 System, and in some cases, specific bands were quantified using the Quantity One software and normalized against b-actin.
| Western blot analysis
| Statistical analysis
GraphPad Prism software was used for data analyses. Data were expressed as mean 6 SEM and analyzed by one-way analysis of variance (ANOVA) followed by Tukey's post-hoc test. Comparison between two experimental groups was based on two-tailed t test. Differences were considered to be statistically significant when P < .05.
| RE S U L TS
3.1 | Expression of S1PR1 in reactive astrocytes in active MS white matter lesions
We investigated the cellular localization of S1PR1 in active human MS brain lesions using an antibody with well-defined specificity to the S1PR1 receptor (Nishimura, Akiyama, Irei, Hamazaki, & Sadahira, 2010) . S1PR1 expression was primarily in GFAP 1 astrocytes near/in active demyelinating lesions ( S1c-e). However, S1PR1 signal in blood vessels appeared to be comparable between control and MS white matter tissues. Western blot analysis showed that S1PR1 levels were variable among different postmortem cases and not statistically different between control and MS groups (n 5 7 each group, not shown). Double immunostaining using tomato-lectin and MHC II antibodies showed that S1PR1 immunoreactivity was rarely localized to microglia/macrophages ( Figure 1c ;
Supporting Information, Figure S1b ). Interestingly, in some MS cases we found strong S1PR1 expression in MHCII 1 infiltrating leukocytes in the perivascular space in actively demyelinating lesions (Figure 1c ), suggesting a potential involvement of S1PR1 signaling in antigenpresenting cell invasion into the CNS and that manipulation of the S1P/S1PR1 axis may confer the suppression of autoimmune demyelination.
| FTY720 prevents cuprizone-induced early oligodendrocyte apoptosis and gliosis
Cuprizone intoxication is known to induce selective apoptosis of oligodendrocytes, which peaks around 2-3 weeks of exposure followed by massive loss of myelin at 4-5 weeks. To investigate if the nonselective S1P receptor modulator, FTY720, prevents cuprizone-induced oligodendrocyte damage, which unlike EAE is independent of autoimmune attacks, we administered FTY720 or vehicle to mice 3 days after the start of the cuprizone diet ( Figure 2a ). Daily intraperitoneal injections of FTY720 did not affect the amount of daily food consumption nor the body weights. However, the FTY720 treatment significantly prevented oligodendrocyte death as determined by TUNEL analysis of mice exposed to cuprizone for 3 weeks (Figure 2b ), which was confirmed by double staining of cleaved/active caspase-3 and mature oligodendrocyte marker GST-p ( Figure 2b ). The average number of TUNEL 1 oligodendrocytes in the caudal corpus callosum after 3 weeks of cuprizone exposure was 218.7 6 112 (mean 6 SEM) for the vehicle injected group and 75.7 6 25.4 for the FTY720 group. Our
finding supports an earlier study that showed co-administration of cuprizone and FTY720 from day 1 prevented oligodendrocyte apoptosis and demyelination (Kim et al., 2011a) . Western blot and quantitative RT-PCR analysis of isolated corpus callosum for mature oligodendrocyte markers further confirmed that FTY720 protected oligodendrocytes ( Figure 2c ). As cuprizone induces prominent astrogliosis and microgliosis before massive demyelination occurs in the caudal region of corpus callosum , we then asked whether FTY720 suppresses glial cell activation. Indeed, FTY720 treatment suppressed the accumulation of reactive astrocytes and activated microglia in the caudal callosum ( Figure 2d , Supporting Information, Figure S2 ) and concurrently prevented cuprizone-induced production of Tnf, Il-1b, and Cxcl3 ( Figure   2e ). These results show that the protective effect of FTY720 against oligodendrocyte apoptosis is associated with blunted activation of astrocytes and microglia and production of proinflammatory mediators.
We next sought to determine how soon FTY720 treatment has to be initiated with cuprizone feeding in order to exert beneficial effects and suppress glial activation. To our surprise, while FTY720 treatment from day 3 after the start of cuprizone intoxication ameliorated glial activation and oligodendrocyte apoptosis (Figure 2 ), FTY720 treatment at later time points, such as from day 10 after cuprizone intoxication, neither effectively protected oligodendrocytes nor suppressed cuprizoneinduced upregulation of inflammatory mediators (Supporting Information, Figure S3 ). These findings suggest that early intervention of S1P receptor signaling is necessary for the protective effect of FTY720 in this model. It also implies critical pathogenic events such as activation of astrocytes and microglia during the initial 10 days contributing to cuprizone-induced oligodendrocyte death and consequent demyelination.
In addition to examining the effect of FTY720 on oligodendrocyte injury, we also tested the effect of two different doses of FTY720 on remyelination since there have been questions whether FTY720 promotes myelin repair (Hu et al., 2011; Kim et al., 2011a; Miron et al., 2010; Slowik et al., 2015) . FTY720 was given from week 5 during cuprizone intoxication when demyelination had occurred and continued for an additional week during recovery with normal diet (Supporting Information, Figure S4a ). We found that FTY720 treatment during the reparative phase, even at the higher dose of 5 mg/kg body weight, did not promote myelin repair (Supporting Information, Figure S4b ) and the number of Olig2 1 oligodendroglial lineage cells and post-mitotic CC1 1 oligodendrocytes in the corpus callosum and cerebellum was 3.3 | Systemically administered FTY720 is converted to pFTY720 in the brain and induces S1P receptor 1 protein downregulation FTY720 readily crosses the BBB due to its lipophilic nature and is phosphorylated by sphingosine kinase II to the active form pFTY720, which is a potent agonist for S1PR1, S1PR4, and S1PR5, less so for S1PR3
and has minimal activity at S1PR2 (Albert et al., 2005; Brinkmann et al., 2002) . We confirmed that peripherally injected FTY720 indeed effectively penetrated the BBB and was phosphorylated to pFTY720 and accumulated in brain parenchyma as determined by mass spectrometry of brain lipid extracts from mice fed cuprizone for 3 weeks and harvested 24 hr after the last dose of FTY720 (Figure 3a) . We previously reported that the brain tissue level of S1P and dihydro-S1P is significantly decreased during cuprizone-induced demyelination as early as 3 weeks after cuprizone intoxication, a time point when oligodendrocyte apoptosis peaks and demyelination remains minimum, and is fully recovered during remyelination period after cuprizone withdrawal (Kim et al., 2012) . As S1P is the endogenous ligand for S1P receptors, were analyzed by lipid chromatography-tandem mass spectrometry. Consistent with our previous findings, the level of S1P was significantly decreased in cuprizone mice when compared with mice with normal diet (Figure 3b ). We found that FTY720 did not prevent the cuprizoneinduced drop of S1P levels ( Figure 3b ) despite that it significantly prevented oligodendrocyte apoptosis (Figure 2 ). Since pFTY720 modulates S1P receptors, this finding suggests that the protective effect of pFTY720 is due to actions at the S1P receptor level. Being a structural analog of S1P, pFTY720 acts as a functional antagonist for S1PR1/S1PR5 by inducing receptor internalization and subsequent degradation (Choi et al., 2011) . Indeed, Western blot analysis of dissected subcortical white matter showed that S1PR1 expression was moderately and S1PR3 and S1PR5 expression was significantly increased in cuprizone mice as compared with controls ( Figure 3c ). Most interestingly, only S1PR1, at the protein level, was completely down-regulated by FTY720 treatment (Figure 3c ).
We did not find any differences in S1pr1 mRNA levels between the vehicle and FTY720 treated groups (Figure 3d ). Together, these data suggest that FTY720 protects oligodendrocytes in the cuprizone demyelination model via functional antagonism of the S1PR1 receptor.
3.4 | Specific S1PR1 modulator protects oligodendrocytes and abrogates cuprizone-induced demyelination Figure S5 ). In agreement with this observation, the transcript levels of Tnf and Ccl3 were significantly lower in CYM5442-treated mice in comparison to vehicle-treated mice ( Figure   4f ). Together, these results demonstrate that selective S1PR1 modulation protects oligodendrocytes and suppresses gliosis and demyelination.
CYM5542 has been previously shown to be able to penetrate the BBB, but its half-life in plasma is relatively short (Gonzalez-Cabrera et al., 2012; Gonzalez-Cabrera et al., 2008) . To determine if CYM5442
was indeed present in the brain of mice that were on CYM5442 treatment for the duration of the experiment, we measured the brain tissue level of CYM5442 using HPLC-MS/MS. The amounts of CYM5442
were determined in brain lipid extracts at the end of 3 weeks of cuprizone feeding. We confirmed that CYM5442 administered peripherally FIG URE 3 FTY720 downregulates S1P receptor 1 protein without affecting brain tissue S1P levels. (a) Mass spectrometry analysis of brain FTY720 and pFTY720 levels of mice exposed to cuprizone for 3 weeks and received daily FTY720 or vehicle from day 3 to day 20. Experimental paradigm was the same as in Figure 2a . n 5 5 mice per group. (b) Reduced brain S1P levels in mice on cuprizone diet for 3 weeks in comparison with normal controls and lack of reversal by FTY720 treatment. Each dot represents an individual mouse brain. (c) Western blot and spot densitometry analysis of brain S1P receptors showing cuprizone-induced upregulation of S1PR1, S1PR3, and S1PR5 and marked decrease of S1PR1 protein levels in the FTY720-treated group. Control, n 5 3; CPZ-veh, n 5 4; CPZ-FTY720, n 5 5. *P < .05; **P < .01; ***P < .001. (d) FTY720 treatment did not affect S1P receptor transcripts as assessed by quantitative RT-PCR analysis. Control, n 5 3; CPZ-veh, n 5 4; CPZ-FTY720, n 5 5. *P < .05, one-way ANOVA with Bonferroni's post hoc test [Color figure can be viewed at wileyonlinelibrary.com] was present in the brain (Table 2 ). Compared with the brain level of pFTY720, the absolute amount of CYM5442 in the brain is much lower. This is likely due to the short half-life of CYM5442 (t 1/2 5 50 min, intravenous, and 3 hr, oral) (Gonzalez-Cabrera et al., 2008) relative to FTY720 (t 1/2 5 1 week) (Gonzalez-Cabrera et al. 2012 ) and that our brain lipid extraction was carried out 24 hr after the last dose of CYM5442. In addition, possible CYM5442 metabolites in the brain
were not analyzed. It should be pointed out that negligible amount of CYM5442 in the brain was detected when CYM5442 was used at a dose of 1 mg/kg body weight (Table 2) , which also failed to suppress neuroinflammation as observed at 3 weeks of cuprizone feeding (data not shown). In summary, the level of CYM5442 was dose-dependently and significantly accumulated in the brain, and effectively prevented oligodendrocyte degeneration and demyelination. 
| CYM5442 modulates early CNS immune responses to cuprizone intoxication
An interesting study recently showed that mature oligodendrocytes are perturbed within the first week of cuprizone intoxication as suggested by downregulation of myelin-associated genes, but not perturbed enough to induce demyelination after just 1 week of cuprizone exposure (Doan et al., 2013) . However, 2 weeks of cuprizone feeding triggers irreversible oligodendrocyte damage that leads to subsequent demyelination 2-3 weeks later, even in the absence of further cuprizone feeding. This study suggests critical pathogenic events during the first 2 weeks in the cuprizone model of demyelination. Consistent with this notion, we found that if FTY720 was given to mice 10 days after the start of cuprizone feeding, it failed to reduce inflammation and protect oligodendrocytes when analyzed at 3 weeks of cuprizone feeding (Supporting Information, Figure S3 ).
Therefore, we reasoned that the period between the 3rd and 10th days is likely a critical time window for inducing irreversible oligodendrocyte damage and setting the stage for subsequent events. We thus performed qRT-PCR analysis of dissected corpus callosum 8 days after the start of cuprizone diet with daily CYM5442 injections from day 3-7 ( Figure 5a ). We first examined the effect of CYM5442 on cell death related gene, in particular BH3-only pro-apoptosis Puma and Noxa that have been implicated in oligodendrocyte apoptosis (Hagemeier et al., 2013) . qRT-PCR analysis revealed that while brief cuprizone exposure for 8 days increased Puma and Noxa expression, CYM5442 treatment did not prevent Puma upregulation but significantly suppressed Noxa line-derived neurotrophic factor (Gdnf) and neuregulin 1 (Nrg1) have been shown to be upregulated only during early stage of cuprizone feeding and decreased during de-or re-myelination processes (Gudi et al., 2011) . We found that Gdnf, but not Nrg1, was significantly elevated after 8 days of cuprizone feeding and was suppressed by CYM5442 treatment (Figure 5c ), which may contribute to subsequent diminished astrogliosis and microgliosis in the CYM5442-treated mice.
Importantly, many inflammatory cytokines such as Tnf, Il-1b, and Il-6
and chemokines such as Cxcl3, Cxcl10, Ccl2, Ccl3, and Ccl5 were robustly induced by brief cuprizone exposure ( Figure 5c ); and CYM5442 treatment significantly abrogated the upregulation of Il-1b, Il-6, Cxcl10, and Cxcl3 and moderately suppressed Ccl3 (Figure 5c ). As CXCL10 is required for microglial recruitment in cuprizone-induced demyelination , the fact that CYM5442 suppressed Cxcl10 induction at the early time point is in agreement with our above findings that subsequent microgliosis at 3 weeks of cuprizone feeding was ameliorated in the CYM5442 group.
We next examined microglia and astrocyte morphology after the short-term cuprizone exposure. Cuprizone intoxication for 8 days 
| CYM5442 abolished cuprizone-induced S1PR1 upregulation and ERK activation in astrocytes
Because CYM5442 selectively downregulated S1PR1 (Figure 6a ) and was sufficient to suppress cuprizone-induced demyelination (Figure 4) , Brain tissue levels of CYM5442 were measured by HPLC-MS/MS 24 hours after the last injection. *P < .05 when compared with CYM5442
(1 mg/kg).
we examined the cellular location of S1PR1. We found that S1PR1 was primarily upregulated in reactive astrocytes, which was completely abolished by CYM5442 (Figure 6c ). In contrast, very few CC1 1 oligodendrocytes or CD68 1 microglia/macrophages were stained positive for S1PR1 (Figure 6d ), a finding in agreement with transcriptome analysis of normal brain parenchymal cells that suggests that S1pr1 is most abundantly expressed in astrocytes ( Figure   6b ; Zhang et al., 2015) . sections from 0 to 0.6 mm lateral and 21 to 22 mm from bregma were counted per animal. Control, n 5 3; CPZ-8 days, n 5 3; CPZ-3 weeks, n 5 2. *P < .05; **P < .01; ***P < .001, one-way ANOVA [Color figure can be viewed at wileyonlinelibrary.com] S1PR1 couples exclusively with Gi and activates downstream signaling such as PI3K/Akt and Ras-mitogen-activated protein kinases ERK1/2 pathways. As activation of S1PR1 can stimulate astrocyte proliferation via the ERK1/2 pathway (Bassi et al., 2006; Osinde, Mullershausen, & Dev, 2007) , we asked if the ERK1/2 pathway is activated in the cuprizone demyelination model and is associated with astrogliosis and if CYM5442 prevents the ERK activation. Western blot analysis showed that the ERK1/2 pathway was in fact activated during cuprizone intoxication and that CYM5442 significantly suppressed cuprizone-induced ERK phosphorylation (Figure 7a ). Interestingly, robust immunosignal for phosphorylated ERK (pERK) was found exclusively in reactive astrocytes in the callosum of mice exposed to cuprizone for 3 weeks and was suppressed by CYM5442 treatment (Figure 7b ). These results suggest that loss of S1PR1 inhibits ERK activation in astrocytes and arrests astroglial proliferation/ accumulation in the white matter track, and support the idea that CYM5442 protects against cuprizone-induced oligodendrocyte damage and demyelination through a mechanism involving downregulation of S1PR1, and suppression of astroglial responses and production of inflammatory mediators.
| D ISC USSION
In this study, we demonstrated that functional antagonism of S1PR1 signaling alone is sufficient to suppress CNS immune responses, oligodendrocyte death and demyelination in a T-cell independent experimental model of MS. We confirmed that FTY720 is activated and accumulated in the brain after systemic administration, and found that daily FTY720 treatment results in complete loss of S1PR1 protein in the brain without affecting its mRNA transcripts, suggesting that prolonged pFTY720 binding to S1PR1 triggers receptor internalization and degradation in vivo (Figure 3 ). We also found that while FTY720 treatment is protective for oligodendrocytes (Figure 2) , it does not promote remyelination in this acute toxin model (Supporting Information, Figure   S4 ), an observation in support of earlier studies (Hu et al., 2011; Kim et al., 2011a) . Among various S1P receptors, we found that S1PR3 is most robustly upregulated at both protein and transcription levels (Figure 3 ). Yet FTY720 treatment does not affect S1pr3 gene upregulation and only moderately suppresses S1PR3. These results suggest that S1PR3 signaling does not play a major pathogenic role in cuprizoneinduced demyelination. In contrast, we found that the beneficial effect of FTY720 can be fully recapitulated with the S1PR1 specific modulator CYM5442 (Figure 4 ). S1PR1 is markedly upregulated in reactive astrocytes in areas that would subsequently undergo demyelination.
The increased S1PR1 expression is also detected in reactive astrocytes in demyelinating MS lesions (Figure 1 ; Supporting Information, Figure   S1 ). Importantly, CYM5442 treatment results in highly selective loss of S1PR1 receptor in the brain (Figure 6 ), and suppression of ERK activation in reactive astrocytes ( Figure 7 ) and subsequent demyelination.
Our in vivo data thus suggest that functional antagonism of S1PR1 sig- (Morell et al., 1998) , even though oligodendrocytes are still viable and myelin not damaged (Tezuka et al., 2013) . However, a continuation of cuprizone feeding for additional 1-2 weeks then results in irreversible oligodendrocyte disruptions that lead to significant demyelination 2-3 weeks later even in the absence of any further cuprizone exposure (Doan et al., 2013) . It is thought that oligodendrocyte death recruits and activates microglia and astrocytes to the injured area.
However, we found that 8 days after cuprizone feeding when no oligodendrocyte death was yet evident, astrocytes and microglia have already started to respond to stressed oligodendrocytes and produce increased levels of cytokines/chemokines ( Figure 5 ). Co-treatment with the S1PR1 receptor modulator CYM5442 (day 3-7) did not prevent cuprizone-induced early loss of "myelin" mRNA in stressed oligodendrocytes, but significantly ameliorated the innate immune responses of astrocytes and microglia. Most interestingly, if S1P receptor modulator was administered starting from 1.5 weeks onwards of cuprizone exposure, the beneficial effect of the drug was then lost (Supporting Information, Figure S3 ), suggesting that critical pathogenic events are instilled during the first 1.5 weeks of cuprizone exposure, a finding in accordance with those from Doan et al. (2013) . Given that S1PR1 is predominantly expressed in astrocytes, we propose that CYM5442 protects oligodendrocytes from further irreversible cell death progression and demyelination in part by modulating astroglial responses during the early pathogenic phase.
Reactive astrocytes can exert both beneficial and detrimental effects in the evolution and progression of neurodegenerative diseases including multiple sclerosis (Pekny et al., 2016; Williams, Piaton, & Lubetzki, 2007) . They may contribute to degeneration by exacerbating inflammatory pathways, secretion of toxic substances, and formation of scars that are inhibitory to repair. Astrocytes can also exert detrimental effects by secreting chemokines that recruit neutrophils, microglia, and macrophages to demyelinating lesions. We previously showed multifaceted cross-talks between microglia and astrocytes and that aberrantly activated astrocytes promote oligodendrocyte damage (Kim, Steelman, Koito, & Li, 2011b; Kim et al., 2012; Li, Baud, Vartanian, Volpe, & Rosenberg, 2005; Li et al., 2008 ). In the current study, we found that functional antagonism of S1PR1 significantly suppressed Il1b, Il-6, Cxcl3, and Cxcl10 transcripts induced by short-term cuprizone exposure ( Figure 5 ). Interleukin (IL)-6 is an inflammatory cytokine that is produced at high levels in active MS lesions (Cannella & Raine, 1995; Erta, Quintana, & Hidalgo, 2012; Woodroofe & Cuzner, 1993) and contributes to EAE pathogenesis by promoting Th17 differentiation (Erta et al., 2012) . Studies with neuronal IL-6 transgenic mice revealed that IL-6 is an important factor in astroglial and microglial activation (Fattori et al., 1995) . Transgenic overexpression of IL-6 under the GFAP promoter results in neurological pathology that includes astrocytosis and neurodegeneration (Campbell et al., 1993) . In the cuprizone demyelination model, Il-6 induced by short-term cuprizone exposure was primarily located to GFAP 1 astrocytes (Tezuka et al., 2013) . Using the GFAP-IL-6 transgenic mice, a recent study reported that chronic IL-6 production by astrocytes induced persistently higher levels of chemokines (CXCL10 and CXCL1) under normal conditions but subdued astroglial and microglial activation after 3 weeks of cuprizone intoxication (Petković, Campbell, Gonzalez, & Castellano, 2016) . Consistent with blunted Il-1b and Il-6 production in CYM5442-treated mice during the early phase of cuprizone intoxication, CYM5442 also prevented the upregulation of chemokine Cxcl10 (Figure 5c ), a key microglial chemoattractant that is primarily produced by reactive astrocytes as ablation of Cxcl10 gene significantly prevented early microglial activation .
Neutrophil infiltration has been suggested as a key contributor for cuprizone-mediated oligodendrocyte damage and demyelination based on studies using bone-marrow chimeric CXCR2 -/-mice (Liu et al., 2010) . CXCL1-3 are proinflammatory, neutrophil-attracting chemokines that signal through CXCR2 (Nolan et al., 2004) . Since Cxcl3 was significantly induced by brief cuprizone exposure and was prevented by CYM5442 co-treatment, we examined the possibility whether the beneficial effect of CYM5442 in the cuprizone model could be mediated by preventing early neutrophil infiltration. Flow cytometry analysis of freshly isolated brain mononuclear cells was used to examine neutrophil populations in the CNS at 8 days after cuprizone feeding.
We observed only a negligible increase in the Gr1 (Kovarik et al., 2004; Lewis et al., 2013) . In spinal cord injury, FTY720 protects secondary tissue damage and enhances functional recovery by inhibiting vascular permeability and astrocyte accumulation without affecting early neutrophil infiltration or microglial responses (Norimatsu et al., 2012) . Moreover, using bone-marrow chimeric mice with genetically labeled peripheral myeloid cells, we found that there was essentially no infiltrating myeloid cells at 8 days of cuprizone exposure ( Figure 5 ). We thus conclude that the beneficial action of CYM5442 in the toxin model of demyelination is due to direct effects on the CNS.
Recently, the pathological implication of aberrant ceramide accumulation in reactive astrocytes in lesion area of MS as well as in the cuprizone-induced demyelination model has been demonstrated by us (Kim et al., 2012) and others (van Doorn et al., 2012) . Along with this, upregulation of S1PR1, 23, 25 expression in astrocytes have been observed in MS lesions (Brana et al., 2014; Van Doorn et al., 2010) . We observed robust upregulation of astrocytic S1PR1 expression only in areas of demyelination in both MS brain (Figure 1 ; Supporting Information, Figure S1 ) and cuprizone mouse brain ( Figure 6 ). This elevated S1PR1 expression could be reflective of compensatory mechanisms after significant decreases of brain S1P levels (Kim et al., 2012; Qin et al., 2010) and/or increased inflammatory mediators such as TNF, which is capable of upregulating S1PR1 in primary human astrocytes (Van Doorn et al., 2010) . Selective ablation of S1pr1 gene in astrocytes mitigated FTY720's therapeutic effect in EAE (Choi et al., 2011) .
Although the mechanism underlying S1PR1 upregulation in astrocytes in MS or animal models of MS remains to be elucidated, accumulating evidence thus far suggests that intracellular S1PR1 signaling in astrocytes may contribute to demyelination pathology and progressive inflammation. Mutant mice with impaired S1PR1 internalization due to phosphorylation-deficient mutation of a serine residue exhibit exacerbated autoimmune neuroinflammation (Garris et al., 2013) . As S1PR1 is abundantly expressed in astrocytes in the CNS lesions, it would be interesting to examine to what extent the altered S1PR1 signaling in astrocytes contributes to the persistently worse EAE symptom seen in these mutant mice. The cuprizone toxin model of demyelination is independent of T cells, and the BBB remains intact. Using LysM-cre tdTomato :Cx3cr1 GFP/1 chimeric mice, we found that there was essentially no infiltrating myeloid cells 8 days after the initiation of cuprizone feeding.
However, specific modulation of S1PR1 with CYM5442 is sufficient in suppressing cuprizone-induced local CNS inflammatory responses (Figure 5) , thereby preventing subsequent astrogliosis, microgliosis, loss of oligodendrocytes and demyelination (Figure 4 ). These data suggest that persistent activation of S1PR1 in astrocytes is involved in reactive astrogliosis and that S1PR1 receptor downregulation at protein levels by either CYM5442 or FTY720 reduces gliosis, inflammatory responses, and overall damage after cuprizone intoxication. In line with this hypothesis, CNP1-driven, oligodendrocyte-specific ablation of S1pr1 gene did not prevent cuprizone-induced demyelination (Kim et al., 2011a) . In contrast, selective inhibition of NFjB activation in astrocytes through transgenic overexpression of a dominant negative IjBa under the control of GFAP promoter was sufficient to protect against cuprizone-induced loss of myelin and associated inflammatory responses whereas inhibition of NFjB in oligodendrocytes had no effect (Raasch et al., 2011) . We found that phosphorylation of ERK1/2 in astrocytes at sites of oligodendrocyte damage was prevented by S1PR1 antagonism (Figure 7 ), in line with a recent study that demonstrated that ablation of Erk2 in the CNS reduced the levels of immune mediators, gliosis and demyelination in the cuprizone model (Okazaki et al., 2016) . Consistent with the critical role of astrocytes in toxin induced demyelination, forced over-activation of astrocytic Nrf2, a main transcriptional regulator for the anti-oxidative defense system, through GFAP-specific deletion of the Nrf2 repressor Keap1, ameliorates the cuprizone-induced loss of oligodendrocytes and inflammation (Draheim et al., 2016) . While the loss of S1pr1 in astrocytes diminished the therapeutic efficacy of FTY720 during EAE (Choi et al., 2011) and FTY720 suppresses pathogenic astrocyte activation and chronic disease progression (Rothhammer et al., 2017) , further investigation of cell-type specific targeting of S1pr1 is required to definitively delineate the exact role of S1PR1 signaling in the context of demyelination and neurodegeneration.
Given the pivotal role of G-protein coupled S1PRs in a wide variety of physiological processes and diseases, developing specific S1PR modulators and molecules akin to FTY720 with reduced side effects is of considerable interest to pharmaceutical industry. FTY720 suppresses lymphocyte circulation for 4-6 weeks even after withdrawal (Johnson et al., 2010) due to its 1-week half-life, which may contribute to infection and melanoma seen in some patients treated with FTY720 (Bourdette & Gilden, 2012) . On the other hand, CYM5442, a selective, CNSpenetrant, peripherally short-acting and S1PR1-specific modulator has been shown to ameliorate EAE symptoms comparable to that of FTY720 but without inducing sustained lymphopenia (Gonzalez-Cabrera et al., 2012) . Using the cuprizone experimental demyelination model that is independent of lymphocytes, we show in the current study that functional antagonism of S1P receptor subtype 1 within the CNS is sufficient to protect against toxin-induced demyelination in vivo.
The beneficial effects of FTY720 treatment or the S1PR1-specific modulator CYM5442 are associated with sustained suppression of S1PR1 protein levels likely due to increased degradation of the receptor, decreased key inflammatory mediators, and diminished reactive gliosis and consequent demyelination. CYM5442, which specifically downregulates S1PR1, exhibits similar extent of protection as FTY720 even at brain tissue level two magnitudes lower than that of FTY720 or pFTY720, suggesting CNS intrinsic S1PR1 as a potential target for preventing toxic demyelination. The fact that S1PR1 signaling modulation has to be initiated early, prior to irreversible oligodendrocyte loss and myelin damage, to be effective also suggests S1PR1-mediated pathways in the initiation of inflammatory processes associated with oligodendrocyte stress and underscores the importance of interventions during the early phase of oligodendrocyte damage. 
